Halozyme Therapeutics Inc.HALO
Close of Friday, October 23, 2026 · Halozyme Therapeutics Inc. is trading above its Pivot, OnlyAlpha's long-term trend line.
Price
$125.64
vs its Pivot
+53.3%
OnlyAlpha Score
88
Trend
Above its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| +9.0% | +86.7% | +91.0% | — | — |
No dividend in the last 12 months.
Who runs and owns it
In these funds
IBB · 0.86%IYH · 0.20%IYY · 0.02%IJH · 0.00%
Suppliers, customers and partners
HALO sells to
| Roche (Genentech) | ENHANZE license |
| Takeda | ENHANZE license |
| Pfizer | ENHANZE license |
| Johnson & Johnson (Janssen) | ENHANZE license |
| AbbVie | ENHANZE license |
| Eli Lilly | ENHANZE license |
| Bristol Myers Squibb | ENHANZE license |
| argenx | ENHANZE license |
From the companies' own annual reports filed with the SEC.
Healthcare · Biotech
Get HALO in your free daily emailAfter every close: whether HALO is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track HALO free → Full Stock check
Track HALO free → Full Stock check